Low serum albumin concentration is a reliable prognostic biomarker associated with an increased risk of all-cause mortality and adverse cardiovascular events across the spectrum of cardiovascular disease.
Does serum albumin concentration predict cardiovascular outcomes and mortality in patients with or at risk for cardiovascular disease?
Serum albumin is a valuable prognostic biomarker across the cardiovascular continuum, where hypoalbuminemia consistently predicts adverse outcomes and mortality.
Concentration of serum albumin (SA), a multifunctional circulatory protein, is influenced by several factors, including its synthesis rate, catabolism rate, extravascular distribution, and exogenous loss. Moreover, both nutritional status and systemic inflammation affect the synthesis of SA. Determining SA concentration aids in risk prediction in various clinical settings. It is of interest to understand the prognostic value of SA in the full spectrum of cardiovascular disease (CVD) in the era of newly developed pharmacological and interventional treatments. Proper interpretation of SA in addition to established risk factors potentially provides a better risk discrimination and thereby presents an option to modify therapeutic strategies accordingly. In this narrative review, we summarize the basic features of SA and its associated physiological functions contributing to its prognostic impacts on CVD. Finally, we discuss the prognostic role of SA in CVDs based on existing evidence.
Chien et al. (Fri,) conducted a review in Cardiovascular disease. Serum albumin concentration was evaluated. Low serum albumin concentration is a reliable prognostic biomarker associated with an increased risk of all-cause mortality and adverse cardiovascular events across the spectrum of cardiovascular disease.